3 results
Identification of supervillin as an ERK3 target: implications for the completion of cytokinesis
Despite potential roles in the tumorigenesis of lung and breast cancer cells, the atypical protein kinase ERK3, a member of the Ras/MAPK pathway, is poorly characterized. The laboratory of Professor Sylvain Meloche, Director of the Signalling and Cell Growth Research Unit, collaborated with the laboratory of Professor Jean-Claude Labbé, Director of the Cell Division and Differentiation Research Unit, both at IRIC, to identify ERK3 targets and better understand its cellular functions. The work carried out led to the identification of supervillin as a target of ERK3. Published in the Journal of Cellular Physiology, the study was jointly led by postdoctoral fellow Joaquim Javary and research advisor Eugénie Goupil, with the collaboration of research advisor Mathilde Soulez.
Four IRIC researchers obtain funding from the Canadian Institutes of Health Research
Resulting from the most recent research grant competition of the Canadian Institutes of Health Research (CIHR), four IRIC researchers obtained funds via the Project grant program.
Identification of a new oncogenic signaling pathway in the development of hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third deadliest cancer in the world. Despite these impressive numbers, the few treatments currently available have only modest effects in affected patients, who are often diagnosed at a late stage of the disease. A better mechanistic understanding of HCC development is required to develop novel targeted therapies that work more efficiently. The team of Professor Sylvain Meloche, Director of the Cell Signaling and Cell Growth Research Unit at IRIC, recently shed light on a previously unknown oncogenic signaling pathway for HCC. Jean-Philippe Guégan and Marjorie Lapouge are the co-first authors of the article published in January in the journal Science Signaling.